...
首页> 外文期刊>Journal of Inclusion Phenomena and Macrocyclic Chemistry >Preparation and in vitro in vivo characterization of polyelectrolyte alginate–chitosan complex based microspheres loaded with verapamil hydrochloride for improved oral drug delivery
【24h】

Preparation and in vitro in vivo characterization of polyelectrolyte alginate–chitosan complex based microspheres loaded with verapamil hydrochloride for improved oral drug delivery

机译:载有维拉帕米盐酸盐的聚电解质藻酸盐-壳聚糖复合物微球的制备和体外体内表征可改善口服药物的递送

获取原文
获取原文并翻译 | 示例

摘要

Verapamil hydrochloride (VH) is a calcium channel blocker. It shows short biological half life (t1/2 4 h) and hence high dosage frequency is required to maintain the desired plasma level upon its oral administration to cardiac patients. Therefore, the present study aims to prepare the controlled release formulation of VH loaded in the alginate–chitosan complex based microspheres. It also involves the study of the effect of drug to polymer ratio and the effect of different concentrations of crosslinking agent (CLA). Chitosan-alginate microspheres were prepared with two different drug to polymer ratios and two different concentrations of CLA (sodium tripolyphosphate) by solvent extrusion method; and were characterized for drug content, particle size, compressibility index, swelling index, surface morphology, in vitro floatability, FTIR, XRPD, DSC, in vitro drug release study and in vivo study. The characterization of fabricated microspheres showed spherical particles with smooth surface of particle size ranging from 1,123.50 to 1,534.40 µm, high drug content (74.8–84.4 %), good flow properties indicated by compressibility index (3.38–7.18 %), high percent swelling index, good floatability (55.4–84.6 % after 12 h). FTIR, XRPD and DSC data supported the formation of a polyelectrolyte alginate chitosan complex as a controlled release microparticulate drug delivery system for verapamil. Microspheres showed 85.0–95.45 % in vitro drug release in 12 h. The prepared microspheres showed controlled drug release during in vivo study with almost same Cmax as that of pure drug but with greater AUC. It was concluded that the alginate–chitosan polyelectrolyte complex based microspheres could be considered for controlled drug delivery of verapamil hydrochloride. The microspheres prepared with high drug to polymer ratio showed good drug content, compressibility index, swelling index, surface morphology, floatability, greater in-vitro drug release and in vivo bioavailability. An increase in concentration in CLA showed a decrease in the compressibility; increase in swelling in pH 1.2, pH 6.8 buffer media; and increase in drug release.
机译:盐酸维拉帕米(VH)是钙通道阻滞剂。它显示出较短的生物学半衰期(t1 / 2 4小时),因此需要高剂量频率才能在向心脏病患者口服时维持所需的血浆水平。因此,本研究旨在制备装载在藻酸盐-壳聚糖复合物微球中的VH控释制剂。它还涉及药物与聚合物比例的影响以及不同浓度的交联剂(CLA)的影响。通过溶剂挤出法制备具有两种不同的药物/聚合物比例和两种不同浓度的CLA(三聚磷酸钠)的壳聚糖-海藻酸盐微球;并针对药物含量,粒度,可压缩性指数,溶胀指数,表面形态,体外漂浮性,FTIR,XRPD,DSC,体外药物释放研究和体内研究进行了表征。制成的微球的表征表明,球形颗粒的表面光滑,粒径范围为1,123.50至1,534.40 µm,药物含量高(74.8–84.4%),流动性好,压缩指数(3.38–7.18%),溶胀指数高,良好的漂浮性(12小时后达到55.4-84.6%)。 FTIR,XRPD和DSC数据支持聚电解质藻酸盐壳聚糖复合物的形成,作为维拉帕米的控释微粒药物递送系统。微球在12小时内显示85.0–95.45%的体外药物释放。制备的微球在体内研究中显示出受控的药物释放,其Cmax与纯药物几乎相同,但AUC更大。结论是基于藻酸盐-壳聚糖聚电解质复合物的微球可以考虑用于盐酸维拉帕米的受控药物递送。用高药物与聚合物的比例制备的微球显示出良好的药物含量,可压缩指数,溶胀指数,表面形态,漂浮性,更大的体外药物释放和体内生物利用度。 CLA浓度的增加表明可压缩性降低。 pH 1.2,pH 6.8缓冲液的溶胀增加;并增加药物释放。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号